Interaction of Macromolecular Drugs with Receptors

  • Josef Pitha
Part of the NATO ASI Series book series (NSSA, volume 113)


Leonardo da Vinci, in that part of his writings which is currently known as Hammer Codex, put forward a hypothesis to explain the circulation of water in the world. Although this renaisance scientist correctly specified all the elements involved, he erroneously rejected rain as a serious factor and suggested that water circulation was due to spontaneous seepage of water from the seas through underground porous rocks to the mountains, from where the rivers flow again. Obviously, we often overestimate the adverse effects of an erroneous hypothesis; such a hypothesis may be temporarily useful and definitely does not limit more rational analyses by others. Appreciation of these aspects of research suitably prepares a reader for the present chapter. Experimental observations described here are hopefully as solid as the rocks, rivers, and rain of da Vinci. We cannot be as certain about the correctness of the hypotheses explaining the observations, but at least the hypotheses are guaranteed harmless to anyone who finds a better explanation.


Membrane Preparation Glycidyl Ether Opiate Receptor Steric Strain Macromolecular Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S.H. Snyder, Neurotransmitter receptor binding and drug delivery, J. Med. Chem., 26:1667 (1983).CrossRefGoogle Scholar
  2. 2.
    K. Barovsky and G. Brooker, (−) − [125I]-Iodopindolol, a new highly selective radioiodinated β-adrenergic receptor antagonist: measurement of β-receptors on intact rat astrocytoma cells, J. Cyclic Nucleot. Res., 6:297 (1980).Google Scholar
  3. 3.
    J. Pitha, B.A. Hughes, J.W. Kusiak, E.M. Dax and S.P. Baker, Regeneration of β-adrenergic receptors in senescent rats: a study using an irreversible binding antagonist, Proc. Natl. Acad. Sci. USA, 79:4424 (1982).CrossRefGoogle Scholar
  4. 4.
    B.L. Largent, A.L. Gundlach, J. Pitha and S.H. Snyder, Measurement of in-vivo β-adrenoceptor turnover in the rat striatum (abstract), Society for Neuroscience Meeting (1985).Google Scholar
  5. 5.
    P.B. Molinoff, α - and β-Adrenergic receptor subtypes: properties, distribution and regulation, Drugs, 28:1 (1984).CrossRefGoogle Scholar
  6. 6.
    J. Pitha, J. Milecki, T. Czajkowska and J.W. Kusiak, β-Adrenergic antagonists with multiple pharmacophores: persistent blockage of receptors, J. Med. Chem., 26:7 (1983).CrossRefGoogle Scholar
  7. 7.
    J. Pitha, S. Zawadzki and B.A. Hughes, Carriers for drugs and enzymes based on copolymers of allyl glycidyl ether with acrylamide, Makromol. Chem., 183:781 (1982).CrossRefGoogle Scholar
  8. 8.
    M.G. Caron, Y. Srinivasan, J. Pitha, K. Kociolek and R.J. Lefkowitz, Affinity chromatography of the β-adrenergic receptor, J. Biol. Chem., 254:2923 (1979).Google Scholar
  9. 9.
    J. Pitha, J. Zjawiony, R.J. Lefkowitz and M.G. Caron, Macro-molecular β-adrenergic antagonists discriminating between receptor and antibody, Proc. Natl. Acad. Sci. USA, 77:2219 (1980).CrossRefGoogle Scholar
  10. 10.
    J.W. Kusiak and J. Pitha, Mapping of mammalian β-adrenoreceptors by use of macromolecular alprenolol derivatives, Biochem. Pharmacol., 31:2071 (1982).CrossRefGoogle Scholar
  11. 11.
    J. Pitha, J. Zjawiony, R.J. Lefkowitz and M.G. Caron, Polymeric drugs by direct copolymerization: polymer of β-adrenergic antagonist alprenolol and its binding to receptors and antibodies, Makromol. Chem., 182:1945 (1981).CrossRefGoogle Scholar
  12. 12.
    M.A. Avery, M.S. Verlander and M. Goodman, Synthesis of 6-aminoisoproterenol, J. Org. Chem., 45:2750 (1980).CrossRefGoogle Scholar
  13. 13.
    K.E. Meier and A.E. Ruoho, Formation of complexes between avidin and β-adrenergic receptors using biotinyl-alprenolol derivatives, Biochem. Biophys. Acta, 761:257 (1983).CrossRefGoogle Scholar
  14. 14.
    J.W. Kusiak and J. Pitha, β-Adrenoreceptor antagonists with multiple pharmacophores: persistent inhibition of rat heart adenylate cyclase, J. Auton. Pharmacol., 3:195 (1983).CrossRefGoogle Scholar
  15. 15.
    J.W. Kusiak, G. Heja and J. Pitha, Two β-adrenergic pharmacophores on the same molecule: complete set of agonist-antagonist combinations, submitted for publication.Google Scholar
  16. 16.
    P.M. Conn, D.C. Rogers, J.M. Stewart, J. Niedel and T. Sheffield, Conversion of a gonadotropin-releasing hormone antagonist to an agonist, Nature, 296:653 (1982).CrossRefGoogle Scholar
  17. 17.
    Y. Shimohigashi, T. Costa, H.-C. Chen and D. Rodbard, Dimeric tetra-peptide enkephalins display extraordinary selectivity for the δ opiate receptor, Nature, 297:333 (1982).CrossRefGoogle Scholar
  18. 18.
    K.A. Jacobson, D. Marr-Leisy, R.P. Rosenkranz, M.S. Verlander, K.L. Melmon and M. Goodman, Conjugates of catecholamines. 1. N-Alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol, J. Med. Chem., 26:492 (1983).CrossRefGoogle Scholar
  19. 19.
    R.W. Kierstead, A. Faraone, F. Mennona, J. Mullin, R.W. Guthrie, H. Crowley, B. Simko and L.C. Blaber, β 1-Selective adrenoceptor antagonists. 1. Synthesis and ß-adrenergic blocking activity of a series of binary (aryloxy)propanolamines, J. Med. Chem., 26:1561 (1983).CrossRefGoogle Scholar
  20. 20.
    P.J. Machin, D.N. Hurst, R.M. Bradshaw, L.C. Blaber, D.T. Burden, A.D. Fryer, R.A. Melarange and C. Shivdasani, β 1-Selective adrenoceptor antagonists. 2. 4-Ether-linked phenoxypropanolamines, J. Med. Chem., 26:1570 (1983).CrossRefGoogle Scholar
  21. 21.
    A. Closse, W. Frick, A. Dravid, G. Bolliger, D. Hauser, A. Saufer and H.-J. Tobler, Classification of drugs according to receptor binding profiles, Naunyn-Schmiedeberg’s Arch. Pharmacol., 327:95 (1984).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Josef Pitha
    • 1
  1. 1.Macromolecular Chemistry Section, National Institute on Aging/GRCNational Institutes of HealthBaltimoreUSA

Personalised recommendations